Pharmaceutical

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster (Shingles): Likelihood of Approval

LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles).

May 17, 2024 - 04:00
LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles).
Read the original article

Tags:

Previous Article

LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihoo...

Next Article

LUNA-18 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders

STAT+: ‘We don’t agree’ on drug pricing policy, FDA chi...

Jun 8, 2023

Why is the healthcare industry hesitant to join the metaverse?

Why is the healthcare industry hesitant to join the met...

Dec 14, 2023

STAT+: Apple Watch pulse oximeter feature removed to comply with ban

STAT+: Apple Watch pulse oximeter feature removed to co...

Jan 18, 2024